Medline ® Abstract for Reference 296
of 'Overview of neurologic complications of non-platinum cancer chemotherapy'
Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
Drug Development Unit, Royal Marsden Hospital, Sutton, London, United Kingdom. email@example.com